Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000151)
SBP Name
BiTE Tarlatamab
Synonyms
AMG-757; AMG757
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS018
Scaffold Info
[1]
Scaffold Name BiTE
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
T-cell surface glycoprotein CD3
BTS Info
Inhibitor Small cell carcinoma of bronchus or lung [ICD-11: 2C25.1]; Prostate cancer [ICD-11: 2C82.Z] N.A. Amgen [1]
Delta-like protein 3
BTS Info
Inhibitor Small cell carcinoma of bronchus or lung [ICD-11: 2C25.1]; Prostate cancer [ICD-11: 2C82.Z] N.A. Amgen; BeiGene [1]
Clinical Trial Information of This SBP
NCT03319940 Click to show the Detail
Indication Small Cell Lung Cancer
Phase Phase I
Title A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of?AMG 757?in Subjects With Small Cell Lung Cancer
Status Recruiting
Sponsor Amgen
NCT04702737 Click to show the Detail
Indication Prostate Cancer
Phase Phase I
Title A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager?AMG 757?in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
Status Not recruiting
Sponsor Amgen
NCT04885998 Click to show the Detail
Indication Small Cell Lung Cancer
Phase Phase I
Title AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Status Active, not recruiting
Sponsor Amgen
NCT05060016 Click to show the Detail
Indication Relapsed/Refractory Small Cell Lung Cancer
Phase Phase II
Title A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Status Active, not recruiting
Sponsor Amgen
NCT05361395 Click to show the Detail
Indication Extensive Stage Small Cell Lung Cancer
Phase Phase I
Title First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Status Recruiting
Sponsor Amgen
NCT05740566 Click to show the Detail
Indication Small Cell Lung Cancer (SCLC)
Phase Phase III
Title Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Status Active, not recruiting
Sponsor Amgen
NCT06064500 Click to show the Detail
Indication Small Cell Lung Cancer
Phase .
Title Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Status Available
Sponsor Amgen
NCT06117774 Click to show the Detail
Indication Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer
Phase Phase III
Title Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (DeLLphi-306)
Status Recruiting
Sponsor Amgen
NCT06211036 Click to show the Detail
Indication Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
Phase Phase III
Title Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Status Recruiting
Sponsor Amgen
References
1 Amgen. Product Development Pipeline. 2021.